-- The U.S. Food and Drug Administration ("FDA") accepted Celcuity's New
Drug Application ("NDA") and granted Priority Review with a Prescription
Drug User Fee Act ("PDUFA") goal date of July 17, 2026, for gedatolisib
in HR+/HER2-/PIK3CA wild-type ("WT") advanced breast cancer ("ABC")
-- Results from PIK3CA WT cohort of Phase 3 VIKTORIA-1 study of gedatolisib
regimens in HR+/HER2- ABC published in Journal of Clinical Oncology
-- Topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1
study are expected to be released in the second quarter of 2026
-- Management to host webcast and conference call today, March 25, 2026, at
4:30 p.m. EDT
MINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the fourth quarter and full year ended December 31, 2025, and other recent business developments.
"We expect this year to be a transformative one for Celcuity. We plan to release topline results from the PIK3CA mutant cohort of our Phase 3 VIKTORIA-1 study in the second quarter of 2026, which, if positive, could potentially advance the standard-of-care second line therapy for a significant number of patients with HR+/HER2- advanced breast cancer," said Brian Sullivan, CEO and co-founder of Celcuity. "Additionally, our efforts remain on track to launch gedatolisib commercially in anticipation of its potential FDA approval in the third quarter of 2026."
Fourth Quarter 2025 Business Highlights and Other Recent Developments
-- In December 2025, updated efficacy and safety results from the Phase 3
VIKTORIA-1 PIK3CA WT cohort were presented at the 2025 San Antonio Breast
Cancer Symposium including patient sub-group analyses, safety analyses
and patient reported outcomes for well-being measures.
-- For patients enrolled in the U.S., Canada, Western Europe, and
Asia Pacific, median progression free survival ("PFS") was 16.6
months with the gedatolisib triplet (gedatolisib + fulvestrant +
palbociclib) versus 1.9 months for fulvestrant (HR=0.14; 95% CI:
0.08-0.28; p<0.0001).
-- The gedatolisib triplet delayed time to definitive deterioration
versus fulvestrant according to patient reported outcomes for
well-being measures that included mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression (the EQ-5D-5L
score). The median time to definitive deterioration was 23.7
months (HR=0.39; 95% CI: 0.25-0.67; p = 0.0003) for patients
treated with the gedatolisib triplet versus 4.0 months for
fulvestrant. Additionally, for the first 8 cycles of treatment,
the patients' assessment of their well-being remained stable
relative to their assessment prior to starting treatment with
gedatolisib.
-- As reported earlier, the gedatolisib triplet was generally well
tolerated in the trial with mostly low-grade treatment-related
adverse events ("TRAEs"). The most common Grade 3+ TRAEs for the
gedatolisib triplet and fulvestrant included neutropenia (62.3%
and 0.8% of patients, respectively); stomatitis (19.2% and 0%);
rash (4.6% and 0%); and hyperglycemia (2.3% and 0%). No patients
experienced Grade 4 hyperglycemia. TRAEs led to the
discontinuation of study treatment in 2.3% of patients in the
gedatolisib triplet group and 0% in the fulvestrant group.
-- In January 2026, the FDA accepted for filing Celcuity's NDA for
gedatolisib in HR+/HER2- PIK3CA WT ABC. The FDA granted Priority Review
and assigned a PDUFA goal date of July 17, 2026.
-- In March 2026, efficacy and safety results from the PIK3CA WT cohort of
the Phase 3 VIKTORIA-1 clinical trial of gedatolisib were published in
the Journal of Clinical Oncology. The cohort consisted of patients with
HR+/HER2-/PIK3CA WT ABC whose disease progressed while on or after
treatment with a CDK4/6 inhibitor and an aromatase inhibitor.
-- As reported previously, the results from the VIKTORIA-1 Phase 3 PIK3CA WT
cohort, established several new milestones in the history of drug
development for HR+/HER2- ABC:
-- The hazard ratio for the gedatolisib triplet is more favorable
than has ever been reported by any Phase 3 trial for patients with
HR+/HER2- ABC.
-- The 7.3 months incremental improvements in median PFS for the
gedatolisib triplet over fulvestrant is higher than has ever been
reported by any Phase 3 trial for patients with HR+/HER2- ABC
receiving at least their second line of endocrine therapy-based
regimen.
-- Gedatolisib is the first inhibitor targeting the PI3K/AKT/mTOR
("PAM") pathway to demonstrate positive Phase 3 results in
patients with HR+/HER2-/PIK3CA WT ABC whose disease progressed on
or after treatment with a CDK4/6 inhibitor.
-- Median duration of response ("DOR") of 17.5 months and incremental
objective response rate ("ORR") improvement of 31% relative to
control for the gedatolisib triplet is the highest reported for an
endocrine therapy-based regimen in second line HR+/HER2- ABC.
Fourth Quarter and Full Year 2025 Financial Results
Unless otherwise stated, all comparisons are for the fourth quarter and full year ended December 31, 2025, compared to the fourth quarter and full year ended December 31, 2024.
Total operating expenses were $49.2 million for the fourth quarter of 2025, compared to $36.4 million for the fourth quarter of 2024. Operating expenses for the full year 2025 were $172.2 million, compared to $113.3 million for the full year 2024.
Research and development ("R&D") expenses were $37.6 million for the fourth quarter of 2025, compared to $33.5 million for the prior-year period. Of the $4.1 million increase in R&D expenses, $8.6 million was related to increased employee and consulting expenses, of which $5.3 million related to commercial headcount additions and other launch-related activities. These amounts were partially offset by a $4.5 million decrease primarily related to costs supporting ongoing activities for the VIKTORIA-1 Phase 3 trial.
R&D expenses for the full year 2025 were $145.0 million, compared to $104.2 million for the prior year. Of the $40.8 million increase in R&D expenses, $26.7 million was related to increased employee and consulting expenses, of which $13.1 million related to commercial headcount additions and other launch-related activities. The remaining $14.1 million increase was primarily related to activities supporting our ongoing clinical trials, a development milestone payment under the license agreement with Pfizer, and other commercial launch-related activities.
General and administrative ("G&A") expenses were $11.6 million for the fourth quarter of 2025, compared to $3.0 million for the prior year period. Of the $8.6 million increase, $6.9 million was related to increased employee-related and consulting expenses, of which $5.4 million related to non-cash stock-based compensation. The remaining $1.7 million increase was primarily related to professional fees, expanding infrastructure costs, and other administrative expenses.
G&A expenses for the full year 2025 were $27.2 million, compared to $9.1 million for the prior year. Of the $18.1 million increase in G&A expenses, $14.9 million was related to increased employee-related and consulting expenses, of which $10.4 million related to non-cash stock-based compensation. The remaining $3.2 million increase was primarily related to professional fees, expanding infrastructure costs, and other administrative expenses.
Net loss for the fourth quarter of 2025 was $51.0 million, or $0.97 per share, compared to a net loss of $36.7 million, or $0.85 per share, for the fourth quarter of 2024. Net loss for the full year 2025 was $177.0 million, or $3.79 per share, compared to a net loss of $111.8 million, or $2.83 per share, in 2024. Non-GAAP adjusted net loss for the fourth quarter of 2025 was $38.4 million, or $0.73 per share, compared to non-GAAP adjusted net loss of $32.3 million, or $0.75 per share, for the fourth quarter of 2024. Non-GAAP adjusted net loss for the full year 2025 was $150.8 million, or $3.22 per share, compared to non-GAAP adjusted net loss of $101.9 million, or $2.58 per share, for 2024. Non-GAAP adjusted net loss excludes stock-based compensation expense, non-cash interest expense, and non-cash interest income. Because these items have no impact on Celcuity's cash position, management believes non-GAAP adjusted net loss better enables Celcuity to focus on cash used in operations. For a reconciliation of financial measures calculated in accordance with generally accepted accounting principles in the United States ("GAAP") to non-GAAP financial measures, please see the financial tables at the end of this press release.
Net cash used in operating activities for the fourth quarter of 2025 was $36.4 million, compared to $27.8 million for the fourth quarter of 2024. Net cash used in operating activities for the full year 2025 was $153.3 million, compared to $83.5 million for the full year 2024. Cash, cash equivalents and short-term investments were $441.5 million at the end of fiscal year 2025 and are expected to finance our operations through 2027.
Webcast and Conference Call Information
(MORE TO FOLLOW) Dow Jones Newswires
March 25, 2026 16:01 ET (20:01 GMT)
Comments